These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12386268)

  • 1. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
    Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
    Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats.
    Hirata M; Endo K; Ohkawa H; Kumaki K; Kubodera N; Slatopolsky E; Kurokawa K; Fukagawa M
    Nephrol Dial Transplant; 2002; 17 Suppl 10():37-40. PubMed ID: 12386267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
    Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
    Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D analogues for secondary hyperparathyroidism.
    Brown AJ; Dusso AS; Slatopolsky E
    Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2).
    Fan SL; Schroeder NJ; Calverley MJ; Burrin JM; Makin HL; Cunningham J
    Nephrol Dial Transplant; 2000 Dec; 15(12):1943-9. PubMed ID: 11096138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.
    Hirata M; Katsumata K; Endo K; Fukushima N; Ohkawa H; Fukagawa M
    Nephrol Dial Transplant; 2003 Sep; 18(9):1770-6. PubMed ID: 12937223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
    J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study.
    Akizawa T; Suzuki M; Akiba T; Nishizawa Y; Ohashi Y; Ogata E; Slatopolsky E; Kurokawa K
    Nephrol Dial Transplant; 2002; 17 Suppl 10():28-36. PubMed ID: 12386266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
    Kinugasa E; Akizawa T; Takahashi J; Nabeshima K; Ogata H; Nakayama F; Ideura T
    Nephrol Dial Transplant; 2002; 17 Suppl 10():20-7. PubMed ID: 12386265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
    Funahashi H; Tanaka Y; Imai T; Wada M; Tsukamura K; Hayakawa Y; Matsuura N; Kikumori T; Oiwa M; Tominaga Y; Takagi H
    J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
    Soliman E; Canaff L; Fox J; Hendy GN
    Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [(3)H]1,25-dihydroxy-22-oxavitamin D(3) compared with [(3)H]1,25-dihydroxyvitamin D(3), determined by micro-autoradiography.
    Koike N; Hayakawa N; Tokuda K; Nishimiya K; Saito K; Stumpf WE
    Nephrol Dial Transplant; 2002; 17 Suppl 10():53-7. PubMed ID: 12386270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Nishii Y; Abe J; Mori T; Brown AJ; Dusso AS; Finch J; Lopez-Hilker S; Morrissey J; Slatopolsky E
    Contrib Nephrol; 1991; 91():123-8. PubMed ID: 1800003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism.
    Hruby M; Ureña P; Mannstadt M; Schmitt F; Lacour B; Drüeke TB
    Nephrol Dial Transplant; 1996 Sep; 11(9):1781-6. PubMed ID: 8918622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
    Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
    J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats.
    Shiizaki K; Negi S; Hatamura I; Sakaguchi T; Saji F; Kunimoto K; Mizobuchi M; Imazeki I; Ooshima A; Akizawa T
    J Am Soc Nephrol; 2005 Jan; 16(1):97-108. PubMed ID: 15574509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism.
    Berdud I; Martin-Malo A; Almaden Y; Tallon S; Concepcion MT; Torres A; Felsenfeld A; Aljama P; Rodriguez M
    Nephrol Dial Transplant; 1996 Jul; 11(7):1292-8. PubMed ID: 8672025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.